| Not Yet Recruiting | A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma. NCT07203898 | Beijing Immupeutics Medicine Technology Limited | Phase 1 |
| Not Yet Recruiting | Tumor Microenvironment Changes After Neoadjuvant Chemo-Immunotherapy in Esophageal Squamous Cell Carcinoma NCT07482774 | Nanjing Medical University | — |
| Not Yet Recruiting | Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma NCT07505186 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Not Yet Recruiting | Evaluation of Skin Tests in Biotherapy Allergies NCT06971848 | University Hospital, Angers | N/A |
| Suspended | Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC NCT07403136 | Fudan University | Phase 2 |
| Recruiting | Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC NCT07519486 | Sichuan University | Phase 2 |
| Not Yet Recruiting | Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC NCT07452601 | Tang-Du Hospital | Phase 2 |
| Recruiting | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types NCT07503808 | IDEAYA Biosciences | Phase 1 |
| Recruiting | A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisp NCT07385001 | Tang-Du Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcin NCT07251062 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 2 / Phase 3 |
| Recruiting | First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors NCT07284186 | Plexium, Inc. | Phase 1 |
| Not Yet Recruiting | Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell NCT07244978 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Recruiting | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced NCT07217171 | EvolveImmune United, Inc | Phase 1 |
| Enrolling By Invitation | Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carci NCT07312578 | Peking University | Phase 2 |
| Recruiting | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations NCT07109726 | Terremoto Biosciences Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumo NCT07128693 | The First Affiliated Hospital of Zhengzhou University | Phase 2 |
| Recruiting | Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma NCT07152678 | National Taiwan University Hospital | Phase 2 |
| Recruiting | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors NCT07090499 | Pfizer | Phase 1 |
| Recruiting | Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Recruiting | Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients NCT07086469 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma NCT07049185 | Peking University Cancer Hospital & Institute | Phase 2 |
| Recruiting | Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cel NCT07188103 | Anhui Provincial Hospital | Phase 2 |
| Not Yet Recruiting | Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC NCT06861894 | Zhigang Li | Phase 2 |
| Withdrawn | S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastat NCT05312372 | Institut de Recherches Internationales Servier | Phase 1 / Phase 2 |
| Recruiting | A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell C NCT06644781 | Daiichi Sankyo | Phase 3 |
| Recruiting | Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Ne NCT07088354 | Tongji Hospital | — |
| Recruiting | A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors NCT06747585 | Alentis Therapeutics AG | Phase 1 / Phase 2 |
| Not Yet Recruiting | Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophag NCT06703047 | Fudan University | Phase 2 |
| Terminated | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMAR NCT06560645 | Prelude Therapeutics | Phase 1 |
| Recruiting | Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell NCT06684600 | Peking University | Phase 2 |
| Active Not Recruiting | Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas NCT06654297 | West China Hospital | Phase 1 |
| Recruiting | Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC NCT06637163 | Shanghai Zhongshan Hospital | Phase 2 |
| Recruiting | Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophag NCT06690476 | Peking University | EARLY_Phase 1 |
| Recruiting | A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Es NCT05563766 | VA Office of Research and Development | Phase 2 |
| Not Yet Recruiting | BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable NCT06588335 | Henan Provincial People's Hospital | Phase 2 |
| Recruiting | Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study NCT07437898 | The Affiliated Hospital of Putian University | Phase 2 |
| Recruiting | Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401) NCT06561178 | Sun Yat-Sen University Cancer Center | — |
| Completed | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors NCT06549816 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer NCT07016724 | The First Affiliated Hospital of Zhengzhou University | Phase 2 |
| Recruiting | Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carci NCT06576973 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Recruiting | Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Ca NCT06509568 | Zhejiang Cancer Hospital | Phase 2 |
| Recruiting | Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma NCT06329869 | National Taiwan University Hospital | Phase 2 |
| Not Yet Recruiting | Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resect NCT06508229 | Harbin Medical University | Phase 2 |
| Recruiting | Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC NCT06601309 | Fujian Medical University Union Hospital | Phase 2 |
| Not Yet Recruiting | A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma NCT06487702 | Rui-hua Xu, MD, PhD | Phase 2 |
| Recruiting | Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma NCT06446726 | Sichuan University | Phase 2 |
| Not Yet Recruiting | Liposomal Irinotecan With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Squamous Cell C NCT06491134 | Hebei Medical University Fourth Hospital | Phase 1 |
| Not Yet Recruiting | Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advance NCT06468644 | Fujian Cancer Hospital | Phase 2 |
| Not Yet Recruiting | Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carci NCT06468670 | Fujian Cancer Hospital | Phase 2 |
| Recruiting | Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advan NCT06885814 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Withdrawn | Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcino NCT06420908 | Hebei Medical University Fourth Hospital | N/A |
| Recruiting | PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant NCT06354140 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 2 |
| Not Yet Recruiting | Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamo NCT06388135 | Yang Jianjun, PhD | Phase 4 |
| Enrolling By Invitation | Cytosponge in Surveillance After Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma NCT06429865 | Changhai Hospital | N/A |
| Not Yet Recruiting | Accurate Diagnosis of the Invasion Depth in ESCC by a Deep Neural Network Analysis of NBI Endoscopy Data NCT06252974 | RenJi Hospital | — |
| Recruiting | Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced NCT06510660 | Fujian Medical University Union Hospital | Phase 2 |
| Recruiting | Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma NCT06988956 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcino NCT06463834 | Fujian Cancer Hospital | Phase 2 |
| Active Not Recruiting | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Es NCT06304974 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Ca NCT06354530 | Army Medical Center of PLA | Phase 2 / Phase 3 |
| Recruiting | Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab NCT06408584 | Anhui Provincial Hospital | — |
| Completed | PPIO-007 Correlation Analysis of Type II Diabetes Mellitus on Short-term and Long-term Outcomes of Patients Wi NCT06333665 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | — |
| Recruiting | A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer NCT06194734 | Beijing Konruns Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma NCT06563869 | The First Affiliated Hospital with Nanjing Medical University | Phase 3 |
| Recruiting | Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy NCT06602843 | Anhui Provincial Hospital | N/A |
| Unknown | Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas NCT06225921 | West China Hospital | Phase 1 |
| Not Yet Recruiting | A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma NCT06152978 | Fudan University | Phase 2 |
| Completed | PPIO-005 The Relationship Between Different Nutritional Pathways and Tumor Outcomes After Minimally Invasive E NCT06192212 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | — |
| Recruiting | TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma NCT06401447 | Fudan University | N/A |
| Recruiting | Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Rese NCT07266493 | Shanghai Zhongshan Hospital | Phase 2 |
| Active Not Recruiting | Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Local NCT06281886 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Tria NCT06178211 | Shanghai Chest Hospital | Phase 2 |
| Recruiting | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors NCT05799274 | Radiopharm Theranostics, Ltd | Phase 1 |
| Active Not Recruiting | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid NCT06084481 | AbbVie | Phase 1 |
| Active Not Recruiting | A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectab NCT06010303 | BeiGene | Phase 2 |
| Terminated | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Can NCT06034860 | Molecular Templates, Inc. | Phase 1 |
| Recruiting | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Meta NCT06047379 | Neonc Technologies, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC NCT06190639 | Zhejiang Cancer Hospital | Phase 2 |
| Recruiting | Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma NCT06165380 | Li Zhang | Phase 2 |
| Recruiting | A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in A NCT06022861 | Shandong Boan Biotechnology Co., Ltd | Phase 3 |
| Completed | High-concentration Small-volume Versus Low-concentration Large-volume Iodine Solution for Esophageal Chromoend NCT06063941 | Xijing Hospital of Digestive Diseases | N/A |
| Recruiting | Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma NCT06056336 | Guo Xufeng | Phase 2 |
| Unknown | Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined NCT05990231 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Active Not Recruiting | Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Che NCT06020885 | Sun Yat-sen University | Phase 1 |
| Not Yet Recruiting | Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma NCT06010212 | The First Affiliated Hospital with Nanjing Medical University | Phase 1 / Phase 2 |
| Recruiting | Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcino NCT05984342 | Affiliated Cancer Hospital of Shantou University Medical College | Phase 1 |
| Not Yet Recruiting | Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (E NCT05896787 | The First Affiliated Hospital of Zhengzhou University | Phase 2 |
| Unknown | Prediction of Lymph Node Status in Stage T1 Esophageal Squamous Cell Carcinoma（RENMIN-237） NCT05980403 | Yongshun Chen | — |
| Recruiting | A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanc NCT05919030 | Renmin Hospital of Wuhan University | Phase 3 |
| Recruiting | Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable NCT05833594 | Anhui Provincial Hospital | — |
| Recruiting | PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC NCT06186609 | Affiliated Hospital of Nantong University | Phase 2 |
| Recruiting | Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esoph NCT06190847 | Anhui Provincial Hospital | — |
| Unknown | Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA NCT05900583 | Guangdong Provincial People's Hospital | — |
| Unknown | XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma NCT05927844 | Fujian Cancer Hospital | Phase 1 |
| Unknown | Dynamic ctDNA Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma NCT06103890 | Hebei Medical University Fourth Hospital | — |
| Recruiting | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanc NCT05319730 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Terminated | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumor NCT05462873 | Novartis Pharmaceuticals | Phase 1 |
| Unknown | Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow NCT05591053 | Activ Surgical | N/A |
| Recruiting | Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative T NCT05281003 | Fudan University | Phase 2 |
| Completed | PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoad NCT05880082 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 2 |
| Recruiting | Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer NCT06173986 | Shanghai Chest Hospital | Phase 1 / Phase 2 |
| Recruiting | Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma NCT05978193 | Shanghai Chest Hospital | Phase 2 |
| Unknown | Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE- NCT05650216 | Shanghai Chest Hospital | Phase 2 |
| Unknown | Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC NCT05626569 | Sun Yat-sen University | Phase 2 |
| Unknown | Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade NCT05265962 | The First Affiliated Hospital of Zhengzhou University | Phase 2 |
| Unknown | Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma NCT05386056 | Peking University | Phase 2 |
| Active Not Recruiting | Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma NCT05659251 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Unknown | Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients NCT05596890 | Guangdong Provincial People's Hospital | Phase 2 |
| Not Yet Recruiting | Sintilimab Plus NCT or NCRT Versus NCRT for ESCC NCT05244798 | Sichuan Cancer Hospital and Research Institute | Phase 3 |
| Unknown | Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC. NCT06125262 | Guangdong Provincial People's Hospital | — |
| Active Not Recruiting | Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC NCT05951127 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | N/A |
| Recruiting | Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma NCT06122493 | Ruijin Hospital | Phase 2 |
| Recruiting | A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors NCT05208762 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Unknown | Peripheral Blood Neoantigen Specific T Cells Predict the Efficacy of Immunotherapy for Esophageal Squamous Cel NCT05633641 | Fudan University | — |
| Unknown | Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TIN NCT05603065 | First Affiliated Hospital Xi'an Jiaotong University | Phase 4 |
| Terminated | Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants NCT05461794 | BeiGene | Phase 2 |
| Unknown | AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma NCT05594914 | The First Affiliated Hospital of University of South China | Phase 2 |
| Unknown | Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamo NCT05561699 | Shanghai Zhongshan Hospital | N/A |
| Completed | Identification of Breath Biomarkers in Esophageal Cancer NCT05557955 | Mian XI | — |
| Recruiting | Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor NCT06190782 | Fudan University | Phase 3 |
| Unknown | Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinom NCT05552651 | Tao Jiang | Phase 2 |
| Active Not Recruiting | Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) NCT05520619 | Sun Yat-sen University | Phase 2 |
| Recruiting | Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resect NCT05507411 | Zhejiang Cancer Hospital | Phase 2 |
| Recruiting | Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma NCT05495152 | Henan Cancer Hospital | Phase 3 |
| Recruiting | Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody NCT05392413 | Nanfang Hospital, Southern Medical University | — |
| Recruiting | A Phase II Study of CRT Combined With QL1706 in ESCC Patients NCT05490719 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell NCT06006650 | Tang-Du Hospital | Phase 2 |
| Unknown | Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC NCT05541445 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 / Phase 2 |
| Enrolling By Invitation | Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell NCT06048926 | The First Affiliated Hospital with Nanjing Medical University | N/A |
| Not Yet Recruiting | Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy NCT05420480 | Shanghai Zhongshan Hospital | N/A |
| Recruiting | Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patient NCT05252078 | Jiangxi Provincial Cancer Hospital | Phase 2 |
| Unknown | Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subj NCT05213312 | Shanghai Zhongshan Hospital | Phase 2 / Phase 3 |
| Enrolling By Invitation | Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carci NCT06303583 | Qiu Guoqin | Phase 1 / Phase 2 |
| Recruiting | Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma NCT05028725 | University of California, San Francisco | N/A |
| Unknown | Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC NCT05394415 | Jiangsu Cancer Institute & Hospital | Phase 1 / Phase 2 |
| Unknown | A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC NCT05317325 | Sichuan University | Phase 1 |
| Unknown | A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma NCT05636150 | Peking Union Medical College Hospital | Phase 2 |
| Unknown | Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcin NCT05038813 | The First Affiliated Hospital of Zhengzhou University | Phase 2 |
| Unknown | Quantitative Analysis of 18F-FAPI Dynamic PET/CT for Accurate Differential Diagnosis of MLN of ESCC NCT05287880 | Fifth Affiliated Hospital, Sun Yat-Sen University | — |
| Recruiting | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in NCT05078047 | UNICANCER | Phase 3 |
| Unknown | Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Eso NCT05170256 | Morten Mau-Sørensen | Phase 2 |
| Active Not Recruiting | Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of NCT04929392 | City of Hope Medical Center | Phase 2 |
| Unknown | Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC NCT05469061 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Unknown | Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade NCT04984018 | The First Affiliated Hospital of Zhengzhou University | Phase 2 |
| Unknown | Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic NCT05199649 | The First Affiliated Hospital of Soochow University | N/A |
| Unknown | A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally NCT04514835 | The First Affiliated Hospital of Zhengzhou University | Phase 2 |
| Recruiting | Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYST NCT04807673 | Tianjin Medical University Cancer Institute and Hospital | Phase 3 |
| Unknown | Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Ca NCT03766178 | The First Affiliated Hospital of Zhengzhou University | Phase 2 |
| Unknown | PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Es NCT05007145 | Fujian Cancer Hospital | Phase 2 |
| Recruiting | RAPA-201 Therapy of Solid Tumors NCT05144698 | Rapa Therapeutics LLC | Phase 1 / Phase 2 |
| Active Not Recruiting | Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced NCT05189730 | Sichuan Cancer Hospital and Research Institute | Phase 2 |
| Unknown | Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification NCT04880811 | Peking University | Phase 2 |
| Recruiting | Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC NCT05775419 | The First Affiliated Hospital with Nanjing Medical University | N/A |
| Unknown | Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal S NCT05028231 | Tongji Hospital | — |
| Unknown | ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma NCT05426850 | Fudan University | — |
| Active Not Recruiting | Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and NCT04868877 | Merus B.V. | Phase 1 / Phase 2 |
| Completed | JAB-3068 Activity in Adult Patients With Advanced Solid Tumors NCT04721223 | Jacobio Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma Af NCT04866381 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Unknown | Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy NCT05044728 | Sichuan Cancer Hospital and Research Institute | Phase 2 |
| Completed | Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody NCT04732494 | BeiGene | Phase 2 |
| Terminated | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid NCT04272034 | Incyte Corporation | Phase 1 |
| Unknown | Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma NCT04851132 | Chinese Academy of Medical Sciences | N/A |
| Unknown | A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell NCT04767295 | Hunan Cancer Hospital | Phase 2 |
| Unknown | Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma NCT04813406 | Henan Provincial People's Hospital | N/A |
| Completed | A Clinical Trial of Esophagectomy for Esophageal Carcinoma NCT06691503 | Sun Yat-sen University | Phase 2 |
| Unknown | Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Es NCT04844385 | Sun Yat-sen University | Phase 2 |
| Completed | Esophageal cAncer Screening Trial NCT04609813 | Changhai Hospital | — |
| Unknown | Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable NCT05174325 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma NCT05740995 | Shanghai Zhongshan Hospital | — |
| Recruiting | Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal NCT04460352 | Karolinska University Hospital | Phase 3 |
| Active Not Recruiting | Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Ca NCT04666090 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Active Not Recruiting | Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC NCT04550260 | AstraZeneca | Phase 3 |
| Unknown | CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer NCT04481100 | Hangzhou Cancer Hospital | Phase 2 |
| Active Not Recruiting | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell NCT04543617 | Hoffmann-La Roche | Phase 3 |
| Active Not Recruiting | Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics NCT04584008 | Peking University | N/A |
| Completed | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid NCT04242199 | Incyte Corporation | Phase 1 |
| Unknown | Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Car NCT04644250 | Wei Ren | Phase 2 |
| Completed | Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients NCT04548440 | Sun Yat-Sen University Cancer Center | Phase 2 |
| Unknown | Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Car NCT04506138 | Zhejiang Cancer Hospital | Phase 1 / Phase 2 |
| Completed | Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcin NCT04435197 | Ruijin Hospital | Phase 2 |
| Completed | The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanc NCT04212598 | Wuhan University | Phase 2 |
| Unknown | Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophag NCT04503967 | Shanghai Zhongshan Hospital | Phase 2 |
| Completed | A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China NCT04121286 | Allist Pharmaceuticals, Inc. | Phase 1 |
| Unknown | Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001) NCT04389177 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Unknown | Surveillance of Peripheral Blood of Lymphocyte and Immunocyte in Neoadjuvant Therapy Patients With Esophageal NCT04440332 | Sichuan Cancer Hospital and Research Institute | — |
| Recruiting | A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC NCT04328948 | National Cancer Center, Japan | Phase 3 |
| Completed | A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Acces NCT04936399 | Bristol-Myers Squibb | — |
| Unknown | Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and NCT04699994 | Keio University | Phase 2 |
| Completed | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma NCT04568200 | Peking Union Medical College Hospital | Phase 2 |
| Completed | HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma NCT06184841 | Peking University Cancer Hospital & Institute | Phase 1 |
| Recruiting | A Study of Sigvotatug Vedotin in Advanced Solid Tumors NCT04389632 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Unknown | Quantitative Assessment of Blood Supply in the Gastic Conduit With Fluorescence Angiography for Esophageal Rec NCT04229524 | Sichuan Cancer Hospital and Research Institute | N/A |
| Completed | Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma NCT05302011 | Peking Union Medical College Hospital | Phase 2 |
| Active Not Recruiting | Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shan NCT04764227 | Fudan University | Phase 2 |
| Unknown | Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Eso NCT04390958 | Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma NCT04177797 | Sichuan Cancer Hospital and Research Institute | Phase 2 |
| Unknown | Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC NCT04229537 | Sinocelltech Ltd. | Phase 1 |
| Active Not Recruiting | Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. NCT04229459 | Baruch Brenner | Phase 2 |
| Terminated | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies NCT04244552 | Atreca, Inc. | Phase 1 |
| Recruiting | A Multicenter Cancer Biospecimen Collection Study NCT04510129 | Cofactor Genomics, Inc. | — |
| Completed | The Efficacy of N-acetylcysteine on Alleviating Symptom Caused by Lugol Chromoendoscopy NCT04764643 | Xijing Hospital of Digestive Diseases | N/A |
| Completed | Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy for Esophageal Squamou NCT04380480 | Sun Yat-sen University | Phase 2 |
| Unknown | Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma NCT04275986 | Chinese Academy of Medical Sciences | Phase 2 |
| Completed | Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma NCT04225364 | Guangzhou Institute of Respiratory Disease | Phase 2 |
| Recruiting | Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Sh NCT04519905 | Fudan University | N/A |
| Unknown | Multimodal Functional Imaging Combined With Metabolomics in Predicting the Efficacy of nCRT for Locally Advanc NCT04759235 | RenJi Hospital | — |
| Unknown | Whether it is More Appropriate to Spray Lugol's Solution From Cervical Esophagus to Esophagogastric Junction NCT04224363 | Shandong University | N/A |
| Unknown | Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma NCT04229849 | Henan Cancer Hospital | Phase 2 |
| Completed | To Compare the Effect of Different Nutritional Pathways on Improving Nutritional Status of Esophageal Cancer P NCT04199832 | Tianjin Medical University Cancer Institute and Hospital | — |
| Recruiting | Registry Platform Gastric/Esophageal Cancer (SAPHIR) NCT04290806 | iOMEDICO AG | — |
| Active Not Recruiting | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumo NCT04140500 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Recruiting | Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cance NCT04138212 | Henan Cancer Hospital | Phase 3 |
| Unknown | Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal Lesions NCT04170257 | Peking University Cancer Hospital & Institute | N/A |
| Completed | Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC NCT03985046 | Fudan University | Phase 2 |
| Terminated | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors NCT04032704 | Seagen Inc. | Phase 2 |
| Unknown | Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal S NCT04063683 | Henan Cancer Hospital | Phase 2 |
| Unknown | Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma NCT04054518 | Tiago Biachi | Phase 2 |
| Unknown | A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiothera NCT03817658 | The First Affiliated Hospital of Zhengzhou University | Phase 2 |
| Completed | A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors NCT04045496 | Jacobio Pharmaceuticals Co., Ltd. | Phase 1 |
| Suspended | A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cel NCT04084158 | Zhejiang Cancer Hospital | Phase 2 |
| Recruiting | Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Ca NCT04009265 | Fujian Medical University Union Hospital | Phase 3 |
| Terminated | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumo NCT04060342 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Phase 1 |
| Unknown | Neoadjuvant Nivolumab for Operable Esophageal Carcinoma NCT03987815 | Samsung Medical Center | Phase 2 |
| Completed | KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma NCT03925870 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 2 |
| Unknown | A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line NCT03958890 | Shanghai Henlius Biotech | Phase 3 |
| Unknown | KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma NCT03927495 | Shanghai Chest Hospital | Phase 2 |
| Unknown | Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Canc NCT03946969 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Unknown | A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer NCT03940001 | Zhejiang Cancer Hospital | EARLY_Phase 1 |
| Unknown | Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01) NCT03940976 | Peking University | Phase 2 |
| Recruiting | Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma NCT03964753 | Hebei Medical University Fourth Hospital | Phase 2 |
| Unknown | Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer NCT03913182 | Shanghai Chest Hospital | Phase 2 |
| Unknown | A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squa NCT03857763 | Hebei Medical University Fourth Hospital | Phase 2 |
| Unknown | Exploration and Verification of DNA Methylolation in Early Screening of Esophageal Cancer NCT03922230 | Nanfang Hospital, Southern Medical University | — |
| Unknown | Quantitative Evaluation of Metastatic Lymph Nodes With Dynamic 18F-FDG PET/CT in Patients With ESCC NCT04514822 | Fifth Affiliated Hospital, Sun Yat-Sen University | N/A |
| Unknown | Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPne NCT03833466 | Peking University | Phase 2 |
| Completed | Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma o NCT03792347 | Hecheng Li M.D., Ph.D | Phase 1 |
| Unknown | Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma NCT03387904 | The First Affiliated Hospital of Zhengzhou University | Phase 2 |
| Completed | Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Using a Multimodal Model Integ NCT07181850 | Nanjing Medical University | — |
| Completed | Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ) NCT03748134 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 |
| Completed | Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of R NCT03322267 | National Taiwan University Hospital | Phase 2 |
| Unknown | Robotic-assisted Esophagectomy vs. Video-Assisted Thoracoscopic Esophagectomy(REVATE) Trial NCT03713749 | Chang Gung Memorial Hospital | N/A |
| Unknown | Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma NCT03790553 | Fudan University | Phase 3 |
| Completed | Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced NCT03600831 | Huai'an First People's Hospital | Phase 2 / Phase 3 |
| Unknown | SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Canc NCT03603756 | Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma NCT03817567 | Sinocelltech Ltd. | Phase 1 / Phase 2 |
| Withdrawn | Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroes NCT03592407 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Changhai Multimodal Esophageal Cancer Cohort NCT06410677 | Wangluowei | — |
| Completed | Impact of Preserving Versus Ligating the Right Gastric Artery on Anastomotic Outcomes After McKeown Esophagect NCT07363629 | The First Hospital of Hebei Medical University | N/A |
| Unknown | Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer NCT03474341 | UMC Utrecht | — |
| Unknown | Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer NCT03377400 | Samsung Medical Center | Phase 2 |
| Unknown | Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma With Positive Circumstantial Resection Margin NCT03273647 | Fudan University | Phase 3 |
| Completed | Moderately Hypofractionated Conformal Radiation Combined With S-1 for Esophageal Squamous Cell Carcinoma NCT03660449 | Sun Yat-sen University | Phase 2 |
| Terminated | Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma NCT03251417 | Peking University | Phase 2 |
| Completed | Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification NCT03888092 | Sunshine Lake Pharma Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | NCI UNC Project ESCC NCT03206125 | National Cancer Institute (NCI) | — |
| Completed | HIV and Other Risk Factors for Esophageal Squamous Cell Carcinoma in Malawi NCT03160209 | UNC Lineberger Comprehensive Cancer Center | — |
| Unknown | Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System NCT03185988 | Shen Lin | Phase 2 |
| Terminated | Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma NCT03278626 | NYU Langone Health | Phase 1 / Phase 2 |
| Completed | Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer NCT03187314 | Hangzhou Cancer Hospital | Phase 2 |
| Completed | Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatm NCT03116152 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| Completed | Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas NCT03797625 | Fudan University | Phase 2 |
| Unknown | Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatmen NCT03224221 | The First Affiliated Hospital of Anhui Medical University | Phase 2 |
| Unknown | Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC NCT03623737 | National Taiwan University Hospital | Phase 2 / Phase 3 |
| Unknown | SIB in Upper Thoracic Esophageal Squamous Cell Carcinoma NCT04115618 | Fudan University | Phase 2 |
| Completed | Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29) NCT02844075 | Yonsei University | Phase 2 |
| Unknown | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC NCT02915432 | Shanghai Junshi Bioscience Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma NCT02964455 | Sun Yat-sen University | Phase 1 |
| Completed | Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma NCT02976909 | Yuhong Li | Phase 2 |
| Unknown | S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma NCT02913066 | Mianyang Central Hospital | Phase 2 |
| Completed | Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esop NCT02916511 | Fudan University | Phase 2 |
| Completed | Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patie NCT02890979 | OHSU Knight Cancer Institute | N/A |
| Completed | Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment NCT02976896 | Yuhong Li | Phase 2 |
| Completed | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors NCT02658214 | AstraZeneca | Phase 1 |
| Unknown | Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas NCT02665702 | Fudan University | Phase 2 |
| Completed | Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102) NCT02649361 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Completed | Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma NCT02645864 | Peking University | Phase 1 |
| Unknown | Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carc NCT02677597 | Fudan University | Phase 3 |
| Unknown | Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus NCT02586753 | Mianyang Central Hospital | Phase 2 |
| Completed | A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCC NCT02647125 | Fudan University | Phase 2 |
| Not Yet Recruiting | CIK in Treating Patients With Esophageal Cancer NCT02490735 | The First People's Hospital of Changzhou | Phase 2 |
| Completed | Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer. NCT02606916 | Sun Yat-sen University | Phase 2 |
| Unknown | Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCR NCT02465736 | Sun Yat-sen University | Phase 3 |
| Unknown | Concurrent Radiotherapy and Weekly Chemotherapy of PF for Postoperative Locoregional Recurrence of Esophageal NCT02325986 | Sun Yat-sen University | Phase 2 |
| Completed | Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal NCT02350517 | Yuhong Li | Phase 2 |
| Unknown | Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell NCT02384811 | Fudan University | Phase 2 |
| Withdrawn | Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell NCT02272699 | Peking University | Phase 2 / Phase 3 |
| Completed | Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma NCT02399306 | Sichuan Cancer Hospital and Research Institute | Phase 3 |
| Completed | A Pilot for a Case-Control Study of Esophageal Squamous Cell Carcinoma in Western Kenya NCT00901173 | National Cancer Institute (NCI) | — |
| Completed | Esophageal Cytology With FISH in Detecting Esophageal Cancer NCT02100189 | OHSU Knight Cancer Institute | N/A |
| Terminated | Proton Beam Therapy to Treat Esophageal Cancer NCT02023541 | Washington University School of Medicine | Phase 1 |
| Completed | The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma NCT06241066 | Tianjin Medical University Cancer Institute and Hospital | — |
| Completed | The Role of Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck C NCT02435602 | Maria Sklodowska-Curie National Research Institute of Oncology | N/A |
| Completed | Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Fail NCT01973725 | Yuhong Li | Phase 2 |
| Completed | Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophagea NCT01822613 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Study of S-1 in Combination With Radiotherapy in Esophageal Cancer NCT01831531 | Fudan University | Phase 2 |
| Completed | Oral Rigosertib for Squamous Cell Carcinoma NCT01807546 | Traws Pharma, Inc. | Phase 2 |
| Terminated | Role of Esophagectomy in Complete Responders to CCRT NCT01740375 | Asan Medical Center | Phase 3 |
| Completed | A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cance NCT01598077 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus NCT01608022 | Yonsei University | Phase 2 |
| Completed | A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemorad NCT01591135 | Fudan University | Phase 3 |